Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 441 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Coronavirus reports – Part 9: “I am very relieved but I... March 4, 2021 FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer May 10, 2018 EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib December 18, 2020 Cancer in My Community: Striving to Lead People to Cancer Care... November 22, 2022 Load more HOT NEWS What People With Cancer and Survivors Should Know About Vaping: An... KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary...
